The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

Stocks•7 May 2026•

1 min read

Canaccord Genuity Cuts TransMedics Price Target Following Q1 Earnings Miss

Key Facts

1Canaccord Genuity Group revised its price target for TransMedics Group down to $124.00 from $152.00 while maintaining a buy rating.

2The company reported a Q1 EPS miss and revenue slightly below consensus, leading to a significant intraday stock drop.

Canaccord Genuity Group has revised its outlook on TransMedics Group (TMDX), lowering the stock's price target to $124.00 from its previous $152.00. The adjustment follows a disappointing Q1 earnings report that saw the company miss expectations on both earnings per share (EPS) and total revenue. This financial underperformance triggered a significant intraday drop in the stock price as investors reacted to margin concerns. Despite the lower price target, the firm maintained its "Buy" rating, suggesting long-term optimism remains intact. Market sentiment has also been weighed down by recent reports of insider selling activity, adding further pressure to the healthcare technology firm's valuation.